Milrinone is an inhibitor of phosphodiesterase 3 (PDE3) that exhibits vasodilatory activity; it is clinically used to treat heart failure. Milrinone increases cAMP, PKA activation, and Ca2+ influx, strengthening contractility. Milrinone also exhibits anticoagulant activity, inhibiting platelet aggregation by preventing Ca2+ release from the dense tubular system.
| Cas No. | 78415-72-2 |
|---|---|
| Purity | ≥98% |
| Formula | C12H9N3O |
| Formula Wt. | 211.22 |
| Chemical Name | 5,8-Dihydro-5-methoxy-8-oxo-1,3-dioxolo[4,5-g]- quinoline-7-carboxylic acid |
| IUPAC Name | 6-methyl-2-oxo-5-pyridin-4-yl-1H-pyridine-3-carbonitrile |
| Synonym | Corotrope; Milrila |
| Melting Point | 264°C |
| Solubility | Soluble in DMSO (>10mg/mL). |
| Appearance | A Off-White to Tan Crystalline Powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | M3344 MSDS PDF |
|---|---|
| Info Sheet | M3344 Info Sheet PDF |
Hiramatsu N, Kageyama K. Anti-thrombotic effect of milrinone is caused by inhibition of calcium release from the dense tubular system in human platelets. Acta Anaesthesiol Scand. 2003 Jan;47(1):53-7. PMID: 12492797.
Yano M, Kohno M, Ohkusa T, et al. Effect of milrinone on left ventricular relaxation and Ca(2+) uptake function of cardiac sarcoplasmic reticulum. Am J Physiol Heart Circ Physiol. 2000 Oct;279(4):H1898-905. PMID: 11009478.
